Corrigendum to “Extended release metfomin for metabolic control assistance during prolonged clozapine administration: A 14 week, double-blind, parallel group, placebo-controlled study” [Schizophr. Res. 113 (1) (2009) 19–26]

The authors recently reported that extended release metformin administration for 14 weeks significantly decreased body weight, serum insulin and the trygliceride/HDL-C ratio in patients undergoing prolonged clozapine administration (Carrizo et al., 2009). We did not provide the gender distribution in this study, and it is a relevant data by itself, and for future comparisons. The authors apologize for this omission, and now provide this data in Table 1. Seventy nine percent of patients were males, and age and body weight change did not differ between both genders.